icon-folder.gif   Conference Reports for NATAP  
 
  65th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 7-11 2014
Back grey_arrow_rt.gif
 
 
 
Time to Viral Suppression [week 2/4] Is Not Related to Achievement of SVR12 in HCV GT1-infected Patients Treated With ABT-450/Ritonavir/Ombitasvir and Dasabuvir With or Without Ribavirin
 
 
  Reported by Jules Levin
AASLD 2014 Nov 7-11 Boston
 
Mark Sulkowski1, Michael W Fried2, Resat Ozaras3, Vasily Isakov4, David Wyles5, Peter Ferenci6, Jordan J Feld7, Filipe Calinas8, Michael Gschwantler9, Darrell Crawford10, Ira M Jacobson11,
Barbara McGovern12, Marti n King12, Edward Gane13
1Johns Hopkins University, Baltimore, Maryland, United States; 2University of North Carolina at Chapel Hill, North Carolina, United States; 3Cerrahpasa Medical School, Istanbul, Turkey; 4Institute of Nutrition, Moscow, Russia; 5University of California San Diego, La Jolla, California, United States; 6Universitaetsklinik fuer Innere Medizin III, Vienna, Austria; 7University of Toronto, Toronto, Ontario, Canada; 8Hosp. St. Antonio dos Capuchos, Lisbon, Portugal; 9Wilhelminenspital, Vienna, Austria; 10University of Queensland, Brisbane, Australia; 11Weill Cornell Medical College, New York, New York, United States; 12AbbVie Inc., North Chicago, Illinois, United States; 13Auckland City Hospital, Auckland, New Zealand
 
......."achievement of SVR12 was not associated with time to viral suppression [week 2 or 4] as assessed by assays examining HCV RNA <25 IU/mL or <15 IU/mL.......Higher baseline HCV RNA level, older age, GT1b subtype, and presence of cirrhosis were associated with a longer time to initial viral suppression <25 IU/mL, but the magnitude of the effect was small and ti me to suppression did not affect achievement of SVR12"

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif

AASLD10.gif

AASLD11.gif

AASLD12.gif

AASLD13.gif

AASLD14.gif